Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
A fibrinolytic agent is a medicine that promotes breakdown of fibrin within a blood clot. These medicines are also called thrombolytic or clot-dissolving drugs. Most therapeutic fibrinolytics activate plasminogen to form plasmin, an enzyme that degrades fibrin. Examples include alteplase, tenecteplase, and reteplase.
read more about fibrinolytic agent ...Fibrinolytic agents are used in selected time-sensitive emergencies in which rapid clot dissolution can restore blood flow. Indications can include acute ischemic stroke, ST-segment elevation myocardial infarction, massive or high-risk pulmonary embolism, and selected blocked vascular catheters. The approved indication differs among individual drugs and formulations. Mechanical clot removal or another reperfusion strategy can be preferred when it is available and appropriate.
Tissue plasminogen activator-type medicines convert plasminogen into plasmin, especially near fibrin-containing clots. Plasmin breaks fibrin strands that provide structural support to the thrombus. Clot dissolution can reopen an obstructed blood vessel and restore oxygen delivery to tissue. The same mechanism can disrupt protective clots elsewhere and cause serious bleeding.
Systemic fibrinolytics are administered intravenously using drug-specific bolus or infusion regimens. Doses can depend on the indication, body weight, symptom timing, and other treatment factors. Emergency teams confirm eligibility through clinical evaluation, imaging, laboratory information, and review of recent procedures or bleeding. Blood pressure, neurological status, heart rhythm, oxygenation, and signs of hemorrhage require close monitoring.
Major bleeding, including intracranial hemorrhage, is the most serious complication. Active internal bleeding, certain recent surgeries or injuries, prior intracranial conditions, severe uncontrolled hypertension, and other factors can make treatment unsafe. Contraindications and precautions differ by indication because the expected benefit and urgency are not the same. Sudden headache, neurological decline, low blood pressure, or visible bleeding during treatment requires immediate evaluation.
Yes. Alteplase is a recombinant tissue plasminogen activator that converts plasminogen to plasmin and promotes fibrin breakdown.
No. A fibrinolytic actively promotes clot breakdown, while an anticoagulant reduces formation or extension of clots through the coagulation cascade.
Yes. Intracranial hemorrhage is a rare but life-threatening risk. Careful eligibility screening and monitoring are required.
No. Their benefit depends on the clot location, severity, timing, available alternatives, and bleeding risk. Many clots are treated with anticoagulation or procedures instead.
Thrombolytic Therapy. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK557411/. Date Accessed August 6, 2026.
ACTIVASE (Alteplase) for Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c669f77c-fa48-478b-a14b-80b20a0139c2. Date Accessed August 6, 2026.
TNKASE (Tenecteplase) for Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e647640d-c395-4b4b-a0be-1162f9c21d84&type=display. Date Accessed August 6, 2026.
RETAVASE (Reteplase) for Injection: Prescribing Information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=e7b63b16-d911-478b-a445-b690a1360b48. Date Accessed August 6, 2026.
Alteplase. StatPearls (NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK499977/. Date Accessed August 6, 2026.